SAN DIEGO, Dec. 18, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it has signed an in-network provider
agreement with Wellmark, Inc., the largest health insurer in
Iowa and South Dakota. The agreement marks Biocept's
third Blue Cross Blue Shield contract and enables patients
diagnosed with cancer the ability to access the Company's
proprietary testing services in-network under their Wellmark health
plan.
"Our assays use a simple blood test to help physicians rapidly
assess the molecular status of a patient's tumor, a critical factor
in the selection of individualized targeted therapy, and provide a
non-invasive option for monitoring response to therapy over time,"
said Biocept's Senior Vice President and Senior Medical Director
Veena Singh, MD. "We are
pleased that patients with Wellmark will now have in-network access
to our highly sensitive Target Selector™ platform."
"The Wellmark contract marks another important milestone in our
initiative to increase access for patients with Blue Cross Blue
Shield to our Target Selector™ platform," said Michael Nall, President and Chief Executive
Officer of Biocept. "In-network status with major health insurers
reduces a barrier for patients diagnosed with cancer and their
physicians to benefit from our proprietary and patented solutions.
With this agreement in place, approximately 200 million patients
have in-network access to our testing platform, with some members
having access via multiple health plans."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
diagnosis and treatment of cancer, our ability to increase patient
access to our technology, and the ability to receive reimbursement
for our tests, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
Securities and Exchange Commission (SEC) filings. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-signs-in-network-provider-agreement-with-wellmark-blue-cross-blue-shield-expanding-coverage-for-its-target-selector-platform-in-iowa-and-south-dakota-300571289.html
SOURCE Biocept, Inc.